85 results about "Nude mouse" patented technology

The application discloses a five-heterocycle compound, a preparation method and application thereof. Specifically disclosed are a compound as shown in formula I, a pharmaceutically acceptable salt or solvate thereof, a composition containing the compound, and a pharmaceutical use of the compound for preparing a drug for treating a disease or disorder related to the mechanism of action of KRAS G12C mutant protein. The five-heterocycle compound in the application has the activity of inhibiting the proliferation of Ba / F3 KRAS-G12C cells, NCI-H358 cells and MIA PaCa-2 cells expressing KRAS G12C mutant protein, and has a good inhibitory effect on the growth of a subcutaneous transplanted tumor of a NCI-H358 nude mouse.

A primer pair, method, and use for rapidly identifying newborn nude mice. On the basis that a deletion mutation occurs in the base G at position 337 of a coding region of the Foxn1 gene in nude mice, a primer pair introducing an enzyme digestion site is designed according to sequence characteristics. Using the genome of a mouse to be tested as a template, the Foxn1 gene is amplified according to a PCR-RFLP method. The PCR product is then digested with a SmaI restriction endonuclease, and the digested product is genotyped by agarose gel electrophoresis. In addition, a reaction system that can be combined with lateral flow technology is screened, thereby achieving instant detection of the newborn nude mice. The method has the characteristics of simple operation, short time consumption, low cost, instant detection, etc.

The application discloses application of Ophisaurus apodus in preparation of a drug for reversing drug resistance of gastric cancer and belongs to the technical field of medicines. The application can reduce tumor volume and size, promote drug resistance cell apoptosis, and reverse the chemotherapeutic drug resistance of a nude mouse with gastric cancer by jointly using Ophisaurus apodus in different parts of the body and cisplatin, by down-regulating P-gp, MRP1 and Bcl-2 protein expression, and by up-regulating Bax protein expression. The effect of the tail + cisplatin group is the most significant.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

The invention discloses a novel application of total glucosides of paeony in preparation of a medicine for treating triple negative breast cancer. In-vitro and in-vivo experiments prove that the total glucosides of paeony can remarkably inhibit proliferation, migration and invasion of triple negative breast cancer cells (MDA-MB-231 and MDA-MB-468), reverse an epithelial-mesenchymal transition process and induce cell apoptosis by inducing mitochondrial injury, inhibiting oxidative phosphorylation and activating a mitochondrial apoptosis pathway. In an MDA-MB-231 cell xenotransplantation tumor nude mouse model, the total glucosides of paeony can effectively inhibit tumor growth. Therefore, the total glucosides of paeony can be used for preparing the medicine for treating the triple negative breast cancer, and a new treatment choice is provided for clinic.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The invention discloses an application of a circRNA marker in diagnosis and treatment of colorectal cancer, the expression level of a circular RNA gene hsacirc0066801 in samples of patients with colorectal cancer and tumor cells is obviously improved, and the overexpression of the circular RNA hsacirc0066801 can obviously promote the proliferation, migration and invasion of the colorectal cancer cells. Meanwhile, knock-down of the hsacirc0066801 can significantly inhibit proliferation, migration and invasion of colorectal cancer cells, in addition, nude mouse tumor formation experiments prove that the tumor volume is significantly increased after overexpression of the hsacirc0066801, and is reduced after knock-down of the hsacirc0066801. Therefore, the hsacirc0066801 can be used as a potential molecular marker and is used as a target spot for clinical diagnosis and treatment of the colorectal cancer.

The present invention relates to an animal model for research on cancer immunotherapy agents, and a preparation method therefor. A nude mouse, which is a mouse model widely used for evaluating the effects of anticancer agents, can verify the efficacy of a cytotoxic anticancer agent, but cannot confirm the effect of an cancer immunotherapy agent because immune function is deficient. However, a cancer animal model according to the present invention has normal immune function, thereby enabling preclinical efficacy of a cancer immunotherapy agent to be accurately predicted, and thus is expected to contribute to improving the prognosis of a patient for whom surgery is not possible.

The application belongs to the field of biomedical engineering, and discloses a human live mucosa organoid and a construction method and application thereof. The construction of the organoid comprises the following steps: preparing a cell gel compound, filling the cell gel compound into a support, implanting the support into a nude mouse subcutaneously after gelation, and obtaining the human live mucosa organoid after culturing for 1-3 weeks. The application also discloses the application of the organoid in disease research or drug screening. The application constructs a sustainable in-vivo biomimetic air-mucosa gas-liquid interface, realizes the transition of mucosa from an "ex-vivo static model" to an "in-vivo dynamic live system", and realizes the comprehensive evaluation of the curative effect of anti-infection drugs from three dimensions of pathogenic bacteria elimination, inflammation reaction regulation and immune cell recruitment inhibition in application, thereby breaking through the limitation of traditional models that can only evaluate the in-vitro bacteriostatic activity and being more consistent with the actual effect of clinical drug treatment.

The invention discloses a benzacridine-3, 4-dicarboximide derivative as well as a preparation method and application thereof, the structure of the benzacridine-3, 4-dicarboximide derivative is shown as I-A, and n is equal to 1, 2, 3 or 4; the invention also discloses hydrochloride of the benzacridine-3, 4-dicarboximide derivative and a preparation method, all the compounds are subjected to CCK-8 experiments to investigate the cytotoxicity to 14 tumor cells and human normal lung embryo fibroblasts, and the compound 4 with the best activity is used for evaluating the cytotoxicity to SK-OV-3 ovarian cancer cell proliferation and invasion, the cytotoxicity to SK-OV-3 ovarian cancer cells, the cytotoxicity to human normal lung embryo fibroblasts and the cytotoxicity to SK-OV-3 ovarian cancer cells and the cytotoxicity to human normal lung embryo fibroblasts. And influence of migration capability. Subsequently, in-vivo anti-tumor activity of the compound 4 is found in a nude mouse xenotransplantation tumor experiment, and whether the compound has toxicity to mice or not is observed through pathological tissue slices under the administration treatment concentration. The invention has great value in discovery of new anti-tumor small molecule drugs and research and development of clinical drugs thereof.

The invention provides an extraction method of high-performance gamma delta T immune cells and application of the high-performance gamma delta T immune cells in tumors. The method comprises the following steps: firstly, separating mononuclear cells from peripheral blood, carrying out activation induction by using a serum-free culture medium containing zoledronic acid, IL-15 and OKT3, and supplementing a culture medium containing IL-2 according to a specific proportion for multiplication culture from the third day of culture. Through the optimization process, the expression rate of TCR-gamma delta < + > is as high as 96.84%, and gamma delta T cells with high activity are obtained. An in-vivo tumor inhibition experiment shows that the cell has a remarkable growth inhibition effect on liver cancer nude mouse transplanted tumor, the effect is equivalent to that of a positive control drug, and obvious toxic and side effects are not observed. The method is stable in process and clear in component, and a reliable technical basis is provided for clinical transformation of gamma delta T cells in immunotherapy of solid tumors and hematologic tumors.

This invention discloses the application of the CEMIP-ITGA5 axis as a target in the preparation of products that regulate epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma, belonging to the fields of tumor molecular biology and precision medicine. Through TCGA-LUAD cohort bioinformatics analysis, immunohistochemical verification of clinical specimens, cell function experiments, and a nude mouse subcutaneous xenograft model, this invention discovers and confirms that the CEMIP-ITGA5 axis participates in regulating epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma. Specifically, CEMIP positively regulates ITGA5 expression, thereby promoting EMT, proliferation, migration, invasion, and in vivo tumorigenesis in lung adenocarcinoma cells. Based on this, the present invention provides two applications: Firstly, by detecting the expression levels of the dual genes CEMIP and ITGA5, a kit for assessing the risk of epithelial-mesenchymal transition (EMT) and metastasis in lung adenocarcinoma can be prepared. The combined detection of CEMIP and ITGA5 can reflect the activation status of the CEMIP-ITGA5 axis at both the upstream regulatory molecule and downstream effector molecule levels, providing auxiliary molecular evidence for assessing EMT and metastasis-related risks in lung adenocarcinoma. Secondly, by targeting and inhibiting the expression or function of CEMIP and / or ITGA5, drugs can be prepared to inhibit epithelial-mesenchymal transition, migration, invasion, and metastasis-related malignant progression in lung adenocarcinoma, effectively reversing the epithelial-mesenchymal transition phenotype and inhibiting tumor malignant progression. This invention provides novel molecular targets and technical solutions independent of known signaling pathways for prognostic assessment and targeted therapy of lung adenocarcinoma.

The application belongs to the technical field of biological medicine, and discloses a kind of targeted inhibition drug and its application in preparation of prevention and treatment of pancreatic cancer preparation.The drug belongs to azetidine compound, which is the targeted inhibitor of STAT3, and can be directly used in the preparation of prevention and treatment of pancreatic cancer drugs, providing a new approach and technical idea for the treatment of pancreatic cancer.Through the international common pancreatic cancer modeling method, combined with experimental conclusion shows that the compound can effectively inhibit the tumor growth state of nude mice pancreatic cancer, inhibit cell growth related protein expression, inhibit mitochondrial complex enzyme activity and induce cell apoptosis, has a significant prevention and treatment effect on pancreatic cancer, and is expected to become a drug for the treatment of pancreatic cancer.

This invention belongs to the field of tumor biology and drug screening technology, specifically disclosing a human EGFR mutation-driven mouse primary lung cancer cell line, its construction method, and its applications. The cell line, ZST-1, is a human EGFR (L858R / T790M) mutation-driven lung cancer cell line derived from mouse primary lung cancer. It is stable, capable of subcutaneous tumor formation in C57BL / 6 mice, and simultaneously expresses Luciferase and tdTomato reporter genes. Its construction method includes obtaining transgenic mice, virus-induced tumor formation, continuous in vivo passage in nude mice, and in vitro culture and screening steps. This cell line can be applied to in vitro screening and efficacy evaluation of human EGFR mutation-targeting drugs, research on EGFR-TKI resistance mechanisms, tumor bioluminescence imaging and fluorescence tracing, and in vivo tumorigenesis and efficacy experiments in an immune-intact C57BL / 6 background.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

The invention discloses an in-vivo evaluation method for the curative effect of NK cells on human ovarian cancer ascites tumor, which comprises the following steps: inoculating human ovarian cancer cells into the abdominal cavity of a female healthy mouse, and establishing a nude mouse model of the human ovarian cancer ascites tumor; nude mouse models are grouped, and intraperitoneal injection administration is carried out on each group of mice; and carrying out fluorescence tracing on the dosed mouse by adopting a fluorescence imaging method, observing the health and death conditions of the mouse at the same time, and judging the treatment effect of the NK cells on the human ovarian cancer ascites tumor. An ovarian cancer mouse model is established through intraperitoneal injection of an SK-OV-3 cell strain, the treatment effect of NK cells on human ovarian cancer ascites tumor in an in-vivo peritoneal complex environment is evaluated, the result is closer to the actual situation, and the detection result is accurate. The compound is applied to preparation of medicines for treating human ovarian cancer ascites tumor, and can significantly prolong the lifetime, reduce the death rate, reduce the tumor load and improve the life quality.

Disclosed is a use of G007-LK in promoting osteogenic differentiation of dental mesenchymal stem cells and bone tissue regeneration. In vitro experiments of the present application show that G007-LK has the ability to induce SHED to form mineralized nodules and promote osteogenic differentiation; in vivo experiments show that G007-LK pretreatment of SHED for 7 days combined with Geistlich Bio-Oss® collagen bone scaffold can enhance the in vivo osteogenic effect of SHED and promote the subcutaneous ectopic osteogenesis of nude mice, indicating that G007-LK has good osteoinductivity and is a potential osteogenic drug. Therefore, G007-LK can promote osteogenic differentiation of dental mesenchymal stem cells and be applied to bone tissue regeneration.

The invention provides a traditional Chinese medicine preparation for treating esophageal cancer and a preparation method thereof, and relates to the technical field of traditional Chinese medicine pharmacy, the traditional Chinese medicine preparation is composed of radix clematidis, salvia chinensis, kelp, radix actinidiae chinensis, glabrous sarcandra herb, lotus leaf base, chaff, adenophora stricta, aspongopus, persimmon calyx, airpotato yam, tangerine pith and nidus vespae; the esophageal cancer resisting effect and safety of the traditional Chinese medicine preparation are systematically verified through in-vitro and in-vivo experiments: the in-vitro experiment shows that the traditional Chinese medicine preparation can remarkably reduce the levels of TNF-alpha, IL-1beta and IL-8 in supernatant of esophageal cancer cells Eca-109, and the anti-tumor effect is achieved by adjusting the inflammation microenvironment; in-vivo experiments show that the traditional Chinese medicine preparation can inhibit the growth of esophageal cancer EC9706 cell nude mouse transplantation tumor; the immune balance of the organism can be remodeled by bidirectionally regulating the immune cell subpopulation, and the anti-tumor immunity is enhanced; meanwhile, liver and kidney injuries to nude mice are not caused under the effective dosage, and a new scheme with safety and effectiveness is provided for clinical treatment of esophageal cancer.

The invention discloses a small molecule peptide with inhibitory activity on breast cancer cells, a preparation and application of the small molecule peptide in treatment of breast cancer, and belongs to the technical field of biomedicine. The amino acid sequence of the small molecule peptide is shown as SEQ ID NO.1. An in-vitro cell experiment proves that the small molecule peptide can remarkably inhibit proliferation of various breast cancer cells and is free of cytotoxicity and good in safety, and the invention further provides a pharmaceutical preparation containing the small molecule peptide. The small molecule peptide and the preparation can significantly inhibit the growth speed of human breast cancer cell MDA-MB-231 transplanted tumor nude mouse tumors, improve the levels of IL-6, IFN-gamma and TNF-alpha cell factors in serum and enhance the immunologic function of nude mice, can be effectively used for breast cancer treatment, provide new candidate drugs and treatment strategies for clinical treatment of breast cancer, and have broad application prospects. Important clinical application values and market prospects are realized.

The present application relates to the field of biological materials, in particular to a preparation method and application of GMS@EVs microspheres loaded with SNAP-VHH fusion protein. The present application constructs a gelatin microsphere delivery system (GMS@EVs) with capture and slow-release functions. The system specifically and efficiently captures CD9-positive exosomes secreted by mesenchymal stem cells through the stable fixation of SNAP-VHH fusion protein on the surface of gelatin microspheres, and realizes the efficient extraction of CD9-positive exosomes from the culture supernatant of mesenchymal stem cells. The present application provides specific reaction sites for the fixation of SNAP-VHH fusion protein by grafting O6-[4-(aminomethyl)benzyl]guanine on the gelatin microspheres, so that the SNAP-VHH fusion protein is stably loaded on the gelatin microspheres. Through experiments, the GMS@EVs microspheres prepared by the present application have controllable slow-release properties for exosomes, and still maintain significant fluorescence signals 48 hours after subcutaneous injection in nude mice, which is at least 16 times longer than the slow-release time of free exosomes (30 minutes of rapid diffusion), realizing the sustained release of exosomes in the local wound and enhancing the durability of the therapeutic effect.

The invention provides a nano-drug delivery platform of a metal organic framework based on Zn / Co-MOF as well as a preparation method and application of the nano-drug delivery platform, and belongs to the technical field of biology and new medicine. The nano-drug delivery platform based on the Zn / Co-MOF metal organic framework comprises a Zn / Co-MOF metal organic framework core, an organic drug composition loaded on the surface of the core and in micropores, and a homologous tumor cell membrane wrapping the outermost layer, wherein the organic pharmaceutical composition is prepared from a tamoxifen-cis-platinum dimer prodrug, a photo-thermal therapeutic agent IR-820 and an immunomodulator metformin. The nano-drug delivery platform provided by the invention visually monitors tumor development and treatment processes in vivo through fluorescence luminescence, integrates chemotherapy-photothermal-endocrine three modes into a whole, has good safety and biocompatibility, shows a remarkable anti-tumor effect in a tumor-bearing nude mouse model, and has good application prospects. And a brand new strategy is provided for treatment of ER + breast cancer.

The invention discloses application of a durian kernel extract to preparation of an anti-cervical cancer medicine and the medicine, and belongs to the technical field of biological medicines. According to the method, dried durian kernels are used as raw materials, non-active lipid interferents are removed through specific petroleum ether ultrasonic degreasing pretreatment, then methanol ultrasonic extraction is adopted, and high-activity extracts of flavonoids and phenolic acid compounds are obtained. The obtained durian kernel extract (DSE) can effectively inhibit the activity of cervical cancer HeLa cells in vitro, can significantly inhibit the growth of subcutaneous transplantation tumors in nude mice in vivo, and shows good biological safety. In conclusion, the extract has clear anti-cervical cancer activity, and provides candidate resources and research basis for developing novel anti-cervical cancer drugs.

This invention relates to a cell-penetrating peptide Y119E and its application in inhibiting the growth of cisplatin-resistant tumors. The invention is characterized by using the cell-penetrating peptide TAT as a carrier to deliver a cell-penetrating peptide containing PGAM1 phosphorylated at position Y119 into tumor cells. The cell-penetrating peptide containing Y119 phosphorylated peptide (Y119E) has the sequence YGRKKRRQRRR-KIWRRSEDVP. The short cell-penetrating peptide Y119E is used in the drug application of inhibiting the growth of cisplatin-resistant tumors. It can effectively inhibit tumor growth subcutaneously in nude mice.

The invention belongs to the technical field of medical treatment, and particularly relates to a pharmaceutical composition and application thereof in preparation of antitumor drugs. The pharmaceutical composition provided by the invention comprises the lenvatinib and the cirametin. It is found for the first time that combination of cirametin and lenvatinib has a synergistic effect on inhibition of liver cancer cell proliferation and migration and induction of apoptosis, and also can synergistically enhance liver cancer cell lysosomal membrane permeability, so that the treatment effect of the pharmaceutical composition on liver cancer is effectively improved. Animal experiments prove that in-vivo combined use of the cirametin and the lenvatinib can more effectively inhibit proliferation of xenotransplantation tumors in nude mice compared with single use of cirametin or lenvatinib. In addition, the pharmaceutical composition can generate an ideal effect in an oral administration mode, and toxic and side effects are controllable. Therefore, the pharmaceutical composition has a good application prospect in the aspect of targeted prevention and treatment of hepatocellular carcinoma, and a new scheme with transformation potential is provided for clinically coping with the drug resistance of the lenvatinib.

The invention belongs to the technical field of biological medicine, and relates to application of H1FX as a therapeutic target and application of three compounds as H1FX inhibitors in preparation of drugs for preventing and / or treating prostatic cancer. Experimental results show that up-regulation of H1FX expression level can promote proliferation of prostate cancer cells, and knock-down of H1FX can inhibit proliferation of prostate cancer cells. H1FX expression up-regulation can significantly promote generation and development of prostate cancer cell line nude mouse subcutaneous tumor formation. Researches show that the three compounds are specifically combined with H1FX, and proliferation of prostate cancer cells and growth of subcutaneous tumors of nude mice with prostate cancer cell strains are inhibited. Therefore, the invention provides a new target for the design of new anti-prostatic cancer drugs, and provides a new thought for the development and preparation of prostatic cancer prevention and / or treatment drugs.

The application provides application of idebenone in preparation of a medicine for treating osteosarcoma. The application of idebenone or a pharmaceutically acceptable salt thereof in preparation of the medicine for treating osteosarcoma is achieved by carrying out proliferation experiments (CCK8 method) and invasion experiments (transwell invasion experiment) of osteosarcoma cell lines in vitro, quantitative analysis of cell viability in the CCK8 method proliferation experiment and quantitative analysis of the number of penetrated cells in the transwell invasion experiment; and constructing a nude mouse CDX (cell-derived xenograft) model, a PDX (human-derived xenograft) model and a tibial orthotopic / metastatic tumor model, intraperitoneally injecting idebenone, and quantitatively analyzing the tumor volume and tumor weight in the CDX model, the tumor volume and tumor weight in the PDX model and the tumor volume, the weight of the affected limb and the number of lung metastases in the tibial orthotopic / metastatic tumor model, which fully indicates that idebenone can inhibit the proliferation, invasion and metastasis of osteosarcoma.

This invention provides a near-infrared photoactivated probe for thionitrite, its preparation method, and its application. The probe is stable, selective, sensitive, and has a low detection limit (142 nM). This probe can detect physiological levels of HSNO in HCT116 cells and can be applied to fluorescence imaging of HSNO in HCT116 colon cancer xenografts in nude mice, providing a visual detection tool for revealing the physiological and pathological mechanisms of HSNO.

The application discloses a selective inhibitor for BRCA mutation and application thereof. Specifically, the application relates to a quinazolinone compound shown in a general formula (I) or a pharmaceutically acceptable salt or a solvate thereof, wherein the compound has better selectivity for BRCA mutation, has a good inhibition rate on the proliferation of BRCA mutant cells at a low concentration, and is superior to existing olaparib and AZD5305 and the like. Through a nude mouse tumorigenesis experiment, it is proved that the drug obviously shows an inhibitory effect on tumor growth at a low drug concentration, and has no obvious toxic side effects.

The invention relates to a 7-ethyl-10-hydroxycamptothecin polymer which has a structural formula as shown in (I), R is S or S-S, m is an integer selected from 20-200, and n is an integer selected from 2-40. The 7-ethyl-10-hydroxycamptothecine SN38 is subjected to structural modification by using beta-CD-PEG, and an-S-or-S-S-ligand with a redox function is used as a connecting arm to prepare the amphiphilic polymer-drug conjugate beta-CD-PEG-R-SN38, so that the water solubility and the stability of the SN38 are improved; meanwhile, the beta-CD-PEG-R-SN38 is prepared into self-assembled nanoparticles, and the self-assembled nanoparticles are high in drug loading capacity, moderate in particle size, uniform in dispersion, low in toxicity and good in biocompatibility, and show an obvious tumor growth inhibition effect in cell tumor-bearing nude mouse models of H22 liver cancer, 4T1 mouse breast cancer, SW480 colon cancer, KB oral epidermal cancer and the like.

The application belongs to the field of medicine and relates to the application of an antitumor compound C11. Specifically, the application relates to the application of a compound C11 and crystal forms, pharmaceutically acceptable salts, esters, hydrates, solvates or prodrugs thereof in the preparation of NME4 protein inhibitors, wherein the structural formula of the compound C11 is shown as formula I. In vitro experimental results show that C11 has a good inhibitory effect on multiple cell lines of colorectal cancer, and the target of the effect is NME4; animal experiments show that C11 can effectively inhibit the growth of colorectal cancer in nude mice. The above results show that the compound C11 can be used as an inhibitor of NME4 and as a drug for tumors with high expression of NME4, in particular as a drug for the clinical treatment of colorectal cancer. The application provides a new therapeutic drug for colorectal cancer, provides a new way to overcome drug resistance of the disease, and provides a new treatment strategy for the clinical treatment of other types of tumors.